TERN Valuation

Terns Pharmaceuticals Inc

Add to Watchlist

Advanced Chart

7.440

-0.12(-1.587%)1D

Overview
Forecast
Valuation
Earnings

TERN Relative Valuation

TERN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TERN is overvalued; if below, it's undervalued.

Historical Valuation

Terns Pharmaceuticals Inc (TERN) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -4.52. The fair price of Terns Pharmaceuticals Inc (TERN) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：7.44

Fair

-6.35

Trailing

Forward

-2.85

EV/EBITDA

Terns Pharmaceuticals Inc. (TERN) has a current EV/EBITDA of -2.85. The 5-year average EV/EBITDA is -1.65. The thresholds are as follows: Strongly Undervalued below -7.53, Undervalued between -7.53 and -4.59, Fairly Valued between 1.28 and -4.59, Overvalued between 1.28 and 4.22, and Strongly Overvalued above 4.22. The current Forward EV/EBITDA of -2.85 falls within the Historic Trend Line -Fairly Valued range.

-2.69

EV/EBIT

Terns Pharmaceuticals Inc. (TERN) has a current EV/EBIT of -2.69. The 5-year average EV/EBIT is -1.64. The thresholds are as follows: Strongly Undervalued below -7.53, Undervalued between -7.53 and -4.59, Fairly Valued between 1.30 and -4.59, Overvalued between 1.30 and 4.24, and Strongly Overvalued above 4.24. The current Forward EV/EBIT of -2.69 falls within the Historic Trend Line -Fairly Valued range.

0.00

Terns Pharmaceuticals Inc. (TERN) has a current PS of 0.00. The 5-year average PS is 11.09. The thresholds are as follows: Strongly Undervalued below -81.89, Undervalued between -81.89 and -35.40, Fairly Valued between 57.58 and -35.40, Overvalued between 57.58 and 104.08, and Strongly Overvalued above 104.08. The current Forward PS of 0.00 falls within the Historic Trend Line -Fairly Valued range.

-6.89

P/OCF

Terns Pharmaceuticals Inc. (TERN) has a current P/OCF of -6.89. The 5-year average P/OCF is -5.08. The thresholds are as follows: Strongly Undervalued below -9.76, Undervalued between -9.76 and -7.42, Fairly Valued between -2.75 and -7.42, Overvalued between -2.75 and -0.41, and Strongly Overvalued above -0.41. The current Forward P/OCF of -6.89 falls within the Historic Trend Line -Fairly Valued range.

-6.19

P/FCF

Terns Pharmaceuticals Inc. (TERN) has a current P/FCF of -6.19. The 5-year average P/FCF is -4.75. The thresholds are as follows: Strongly Undervalued below -9.15, Undervalued between -9.15 and -6.95, Fairly Valued between -2.55 and -6.95, Overvalued between -2.55 and -0.36, and Strongly Overvalued above -0.36. The current Forward P/FCF of -6.19 falls within the Historic Trend Line -Fairly Valued range.

Terns Pharmaceuticals Inc (TERN) has a current Price-to-Book (P/B) ratio of 2.17. Compared to its 3-year average P/B ratio of 1.61 , the current P/B ratio is approximately 34.50% higher. Relative to its 5-year average P/B ratio of 1.40, the current P/B ratio is about 54.78% higher. Terns Pharmaceuticals Inc (TERN) has a Forward Free Cash Flow (FCF) yield of approximately -11.24%. Compared to its 3-year average FCF yield of -16.73%, the current FCF yield is approximately -32.81% lower. Relative to its 5-year average FCF yield of -22.72% , the current FCF yield is about -50.53% lower.

2.17

P/B

Median3y

1.61

Median5y

1.40

-11.24

FCF Yield

Median3y

-16.73

Median5y

-22.72

Competitors Valuation Multiple

The average P/S ratio for TERN's competitors is 35.44, providing a benchmark for relative valuation. Terns Pharmaceuticals Inc Corp (TERN) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TERN.O

Terns Pharmaceuticals Inc

Maravai LifeSciences Holdings Inc

Relay Therapeutics Inc

108.43

708.61M

PVLA.O

Palvella Therapeutics Inc

Loss

591.59M

Performance Decomposition

Market capitalization of TERN increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of TERN in the past 1 year is driven by Unknown.